CAR-T cells for cancer immunotherapy  

作　　者：Yangyang Xie Xiaotong Li Jingyi Wu Huiling Zeng Hamza Boucetta Binru Wang Pei Yang Wei He 

机构地区：[1]School of Pharmacy,China Pharmaceutical University,Nanjing 210000,China [2]School of Science,China Pharmaceutical University,Nanjing 210000,China [3]Shanghai Skin Disease Hospital,Tongji University School of Medicine,Shanghai 200443,China

出　　处：《Chinese Chemical Letters》2023年第9期55-64,共10页中国化学快报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.81872823,82073782 and 82241002);the Shanghai Science and Technology Committee(No.19430741500);National Innovation and Entrepreneurship Training Program for Undergraduate(No.202210316145);the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(No.zdsys202103)。

摘　　要：Adoptive immunotherapy expressing synthetic chimeric antigen receptors(CAR)on T cells through in vitro modifications represents a new and innovative strategy in cancer treatment.This new approach enables T cells to recognize and bind tumor antigens via a single-chain variable fragment recognition domain,circumventing the restriction of major histocompatibility complex.This review summarized the structure/design of CAR-T cells and the evolution process this technology went through,displaying the theoretical foundation for CAR-T therapy,the marketed products and the latest preclinical and clinical research progress.Finally,we provided perspectives on this technology’s development and potential future applications,especially for treating hematological malignant and solid tumors.

关 键 词：CAR-T cells Cancer Immunotherapy Therapeutic techniques Marketed drugs Universal CAR-T Cell Therapy 

分 类 号：R730.51[医药卫生—肿瘤]